Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 anifrolumab study in active proliferative lupus nephritis
2023-506359-68-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Anifrolumab arm with Placebo arm (2 arms). Primary endpoint: Complete renal response at Week 52. Planned start Apr 2022; status: authorised.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-506359-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506359-68-00.